How much revenue did Pharmaron Beijing Co generate this year?
Pharmaron Beijing Co has achieved a revenue of 12.65 B CNY this year.
Pharmaron Beijing Co Revenue 2024
Pharmaron Beijing Co Revenue
12.65 B CNY
Ticker
300759.SZ
ISIN
CNE100003JW4
In 2024, Pharmaron Beijing Co's sales reached 12.65 B CNY, a 9.61% difference from the 11.54 B CNY sales recorded in the previous year.
The Pharmaron Beijing Co Revenue history
| YEAR | REVENUE (undefined CNY) | GROSS MARGIN (%) |
|---|---|---|
| 2026e | 16.37 | 25,14 |
| 2025e | 14.39 | 28,60 |
| 2024e | 12.65 | 32,54 |
| 2023 | 11.54 | 35,67 |
| 2022 | 10.27 | 36,67 |
| 2021 | 7.44 | 35,95 |
| 2020 | 5.13 | 37,38 |
| 2019 | 3.76 | 35,49 |
| 2018 | 2.91 | 32,67 |
| 2017 | 2.29 | 32,68 |
| 2016 | 1.63 | 28,96 |
| 2015 | 1.13 | 27,45 |
Pharmaron Beijing Co Revenue, EBIT, Net Income CNE100003JW4 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Pharmaron Beijing Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Pharmaron Beijing Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Pharmaron Beijing Co’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Pharmaron Beijing Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Pharmaron Beijing Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Pharmaron Beijing Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Pharmaron Beijing Co’s growth potential.
Pharmaron Beijing Co Revenue, EBIT and net profit per share
| Date | Pharmaron Beijing Co Revenue | Pharmaron Beijing Co EBIT | Pharmaron Beijing Co Net Income |
|---|---|---|---|
| 2026e | 16.37 B undefined | 2.49 B undefined | 2.26 B undefined |
| 2025e | 14.39 B undefined | 2.12 B undefined | 1.91 B undefined |
| 2024e | 12.65 B undefined | 1.81 B undefined | 1.82 B undefined |
| 2023 | 11.54 B undefined | 1.79 B undefined | 1.6 B undefined |
| 2022 | 10.27 B undefined | 1.72 B undefined | 1.37 B undefined |
| 2021 | 7.44 B undefined | 1.51 B undefined | 1.66 B undefined |
| 2020 | 5.13 B undefined | 1.09 B undefined | 1.17 B undefined |
| 2019 | 3.76 B undefined | 706.7 M undefined | 547.2 M undefined |
| 2018 | 2.91 B undefined | 449.8 M undefined | 333 M undefined |
| 2017 | 2.29 B undefined | 358.6 M undefined | 230.9 M undefined |
| 2016 | 1.63 B undefined | 189.3 M undefined | 176.9 M undefined |
| 2015 | 1.13 B undefined | 80.8 M undefined | 73.8 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2015 | 1.13 B CNY | 80.8 M CNY | 73.8 M CNY |
| 2016 | 1.63 B CNY | 189.3 M CNY | 176.9 M CNY |
| 2017 | 2.29 B CNY | 358.6 M CNY | 230.9 M CNY |
| 2018 | 2.91 B CNY | 449.8 M CNY | 333 M CNY |
| 2019 | 3.76 B CNY | 706.7 M CNY | 547.2 M CNY |
| 2020 | 5.13 B CNY | 1.09 B CNY | 1.17 B CNY |
| 2021 | 7.44 B CNY | 1.51 B CNY | 1.66 B CNY |
| 2022 | 10.27 B CNY | 1.72 B CNY | 1.37 B CNY |
| 2023 | 11.54 B CNY | 1.79 B CNY | 1.6 B CNY |
| 2024e | 12.65 B CNY | 1.81 B CNY | 1.82 B CNY |
| 2025e | 14.39 B CNY | 2.12 B CNY | 1.91 B CNY |
| 2026e | 16.37 B CNY | 2.49 B CNY | 2.26 B CNY |
Pharmaron Beijing Co stock margins CNE100003JW4 ·
The Pharmaron Beijing Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pharmaron Beijing Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pharmaron Beijing Co.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Pharmaron Beijing Co's sales revenue. A higher gross margin percentage indicates that the Pharmaron Beijing Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Pharmaron Beijing Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Pharmaron Beijing Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Pharmaron Beijing Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Pharmaron Beijing Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Pharmaron Beijing Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Pharmaron Beijing Co Margin History
| Pharmaron Beijing Co Gross margin | Pharmaron Beijing Co Profit margin | Pharmaron Beijing Co EBIT margin | Pharmaron Beijing Co Profit margin |
|---|---|---|---|
| 2026e | 35.67 % | 15.18 % | 13.82 % |
| 2025e | 35.67 % | 14.72 % | 13.24 % |
| 2024e | 35.67 % | 14.27 % | 14.42 % |
| 2023 | 35.67 % | 15.47 % | 13.88 % |
| 2022 | 36.67 % | 16.78 % | 13.39 % |
| 2021 | 35.95 % | 20.29 % | 22.31 % |
| 2020 | 37.38 % | 21.17 % | 22.84 % |
| 2019 | 35.49 % | 18.81 % | 14.56 % |
| 2018 | 32.67 % | 15.47 % | 11.45 % |
| 2017 | 32.68 % | 15.63 % | 10.06 % |
| 2016 | 28.96 % | 11.58 % | 10.82 % |
| 2015 | 27.45 % | 7.16 % | 6.54 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2015 | 27.45 % | 7.16 % | 6.54 % |
| 2016 | 28.96 % | 11.58 % | 10.82 % |
| 2017 | 32.68 % | 15.63 % | 10.06 % |
| 2018 | 32.67 % | 15.47 % | 11.45 % |
| 2019 | 35.49 % | 18.81 % | 14.56 % |
| 2020 | 37.38 % | 21.17 % | 22.84 % |
| 2021 | 35.95 % | 20.29 % | 22.31 % |
| 2022 | 36.67 % | 16.78 % | 13.39 % |
| 2023 | 35.67 % | 15.47 % | 13.88 % |
| 2024e | 35.67 % | 14.27 % | 14.42 % |
| 2025e | 35.67 % | 14.72 % | 13.24 % |
| 2026e | 35.67 % | 15.18 % | 13.82 % |
Pharmaron Beijing Co Aktienanalyse
What does Pharmaron Beijing Co do?
Pharmaron Beijing Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Pharmaron Beijing Co's Sales Figures
The sales figures of Pharmaron Beijing Co originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Pharmaron Beijing Co’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Pharmaron Beijing Co's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Pharmaron Beijing Co’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Pharmaron Beijing Co stock
How much was the turnover of the company Pharmaron Beijing Co compared to the previous year?
The revenue of Pharmaron Beijing Co has increased by 9.61% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Pharmaron Beijing Co?
The revenue of Pharmaron Beijing Co is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Pharmaron Beijing Co measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Pharmaron Beijing Co so important for investors?
The revenue of Pharmaron Beijing Co is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Pharmaron Beijing Co pay?
Over the past 12 months, Pharmaron Beijing Co paid a dividend of 0.2 CNY . This corresponds to a dividend yield of about 0.72 %. For the coming 12 months, Pharmaron Beijing Co is expected to pay a dividend of 0.22 CNY.
What is the dividend yield of Pharmaron Beijing Co?
The current dividend yield of Pharmaron Beijing Co is 0.72 %.
When does Pharmaron Beijing Co pay dividends?
Pharmaron Beijing Co pays a quarterly dividend. This is distributed in the months of July, July, August, July.
How secure is the dividend of Pharmaron Beijing Co?
Pharmaron Beijing Co paid dividends every year for the past 8 years.
What is the dividend of Pharmaron Beijing Co?
For the upcoming 12 months, dividends amounting to 0.22 CNY are expected. This corresponds to a dividend yield of 0.79 %.
In which sector is Pharmaron Beijing Co located?
Pharmaron Beijing Co is assigned to the 'Health' sector.
Wann musste ich die Aktien von Pharmaron Beijing Co kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Pharmaron Beijing Co from 6/27/2024 amounting to 0.2 CNY, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.
When did Pharmaron Beijing Co pay the last dividend?
The last dividend was paid out on 6/27/2024.
What was the dividend of Pharmaron Beijing Co in the year 2023?
In the year 2023, Pharmaron Beijing Co distributed 0.2 CNY as dividends.
In which currency does Pharmaron Beijing Co pay out the dividend?
The dividends of Pharmaron Beijing Co are distributed in CNY.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Pharmaron Beijing Co
Our stock analysis for Pharmaron Beijing Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharmaron Beijing Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Pharmaron Beijing Co Revenue
- Pharmaron Beijing Co Net Income
- Pharmaron Beijing Co P/E
- Pharmaron Beijing Co P/S
- Pharmaron Beijing Co EBIT
- Pharmaron Beijing Co Dividend
- Pharmaron Beijing Co Stocks
- Pharmaron Beijing Co Market capitalization
- Pharmaron Beijing Co Debt
- Pharmaron Beijing Co Liabilities
- Pharmaron Beijing Co Equity
- Pharmaron Beijing Co AAQS
- Pharmaron Beijing Co Employees
- Pharmaron Beijing Co ROE
- Pharmaron Beijing Co ROA
- Pharmaron Beijing Co ROCE